ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イバンドロネート

Ibandronate

HCID 60852
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
114084-78-5
標準SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
分子式
C9H23NO7P2
平均分子量
319.23 g/mol
単同位体質量
319.09497607

概要

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid]. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003.

名称と識別子

優先名称
Ibandronate
IUPAC
[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
現地名
イバンドロネート
英語名
Ibandronic acid
分子式
C9H23NO7P2
分子量
319.23

名称と別名

Ibandronic AcidIbandronate114084-78-5BondenzaIasibon{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acidIbandronic Acid TevaIbandronic Acid AccordIbandronic Acid Sandoz[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acidAcido ibandronicoacide ibandronique
名称をさらに表示
イバンドロネートイバンドロン酸1-ヒドロキシ-3-(メチルペンチルアミノ)プロピリデンビスホスホン酸[3-(メチルペンチルアミノ)-1-ヒドロキシプロピリデン]ビスホスホン酸{1-ヒドロキシ-3-[メチル(ペンチル)アミノ]-1-ホスホノプロピル}ホスホン酸[1-ヒドロキシ-3-[メチル(ペンチル)アミノ]プロピリデン]ビス(ホスホン酸)[1-ヒドロキシ-3-(ペンチルメチルアミノ)プロピリデン]ビスホスホン酸イバンドロナート1-ヒドロキシ-3-[メチル(ペンチル)アミノ]プロピリデンビスホスホン酸3-(メチルペンチルアミノ)-1-ヒドロキシプロパン-1,1-ジイルビス(ホスホン酸)IbandronicBPH 24Ibadronic AcidIbandronate AcidIBANDRONIC ACID-D3Tirofiban Impurity 67Ibandronic acid USP/EP/BPIbandronic Acid (Ibandronate)[1-Hydroxy-3-(MethylpentylaMino)propylidene]diphosphonic Acid
UMD7G2653WNSC-722623DTXSID5048340RPR-102289AQuodixor(1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonic acidacidum ibandronicumRefChem:56785

物性

構造計算による物性

XLogP
-4.1
極性表面積
139 Ų
水素結合供与体数
5
水素結合受容体数
8
回転可能結合数
9
重原子数
19
形式電荷
0
複雑度
342

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-2.1
Solubility · 2 件

Freely soluble

1.34e+01 g/L

Human Drugs · 6 件

Breast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Melting Point113-115
Physical DescriptionSolid
Collision Cross Section170.12 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
113 · 113-115°C
沸点
587.8 · 587.8±60.0 °C(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (95.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (95.2%)

毒性情報

Exposure RoutesPoorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Toxicity Summary · 1 件

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Signs and SymptomsLD<sub>50</sub> = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingIbandronate's protein binding in serum varies from 85.7-99.5% over a concentration of 0.5-10ng/mL, but is generally 86% across a concentration range of 20-2000ng/mL.
Pharmacodynamics · 1 件

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women. The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours. Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.

Mechanism of Action · 1 件

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. ibandronate also activated caspase-3 which contribute to apoptosis.

Biological Half-LifeThe half life of ibandronate in postmenopausal women ranges from 37-157 hours.
Metabolism/Metabolites · 2 件

Ibanronate is not metabolized in humans.

関連反応

36 件
反応記録を作成
HRID 229896 の反応式
HRID 229896反応物として
HRID 229897 の反応式
HRID 229897反応物として
HRID 229898 の反応式
HRID 229898反応物として
HRID 229899 の反応式
HRID 229899反応物として
HRID 229900 の反応式
HRID 229900反応物として
HRID 229901 の反応式
HRID 229901反応物として
HRID 229902 の反応式
HRID 229902反応物として
HRID 229903 の反応式
HRID 229903反応物として
前へ1 / 5 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
114084-78-5
PubChem CID
60852
DTXSID
DTXSID5048340
ChEMBL
CHEMBL997
UNII
UMD7G2653W
EC Number
688-095-0
Nikkaji
J476.066B
比重(密度)
1.449 · 1.449±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
水性ベース(わずかに)、メタノール(わずかに)、水(わずかに)
酸解離定数(Pka)
1.6 · 1.60±0.10(Predicted)
外見
個体
色
ホワイトからオフホワイト
安定性
吸湿性
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CCN(C)CCCCC
CAS データベース
114084 · 114084-78-5(CAS DataBase Reference)
EPAの化学物質情報
1 · Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5)

化学的性質

化学的特性White Solid

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

ibandronate

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub> = 811 mg/kg (rat, oral)

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

No evidence of ibandronate being metabolized in humans. Route of Elimination: Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces. Half Life: 10-60 hours

FDA Pharmacological Classification · 5 件

UMD7G2653W

IBANDRONIC ACID

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Ibandronic acid is a Bisphosphonate.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 4 件

Oral ibandronate is 0.63% bioavailable. In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL. The Tmax is approximately 1 hour, while Cmax varies depending on dose. A 2mg intravenous dose of ibandronate has an AUC of 316ng\*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng\*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng\*h/mL.

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.

The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.

The total clearance of ibandronate is 84-160mL/min.

Cellular LocationsCytoplasm
Metabolite PathwaysIbandronate Action Pathway

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >100

For the treatment and prevention of osteoporosis in postmenopausal women.

応用分野 · 2 件

説明This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.

使用A biphosphonate bone resorption inhibitor.

上流・下流製品情報

下流製品

イバンドロネートナトリウム一水和物